Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab versus tacrolimus for primary membranous nephropathy
2023-506525-11-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Mar 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in idiopathic membranous glomerulonephritis (IMG) comparing Obinutuzumab arm with Tacrolimus arm (2 arms). Primary endpoint: Complete remission at Week 104. Planned start Mar 2024; status: authorised.
02
Drugs
obinutuzumabtacrolimus
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on 2023-506525-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506525-11-00.